natgillin/translations-raw huggingface dataset:
CHMP besluttede, at fordelene ved Peyona opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Peyona.
The CHMP decided that Peyona’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved PhotoBarr opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that PhotoBarr’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Plavix opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Plavix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Pradaxa opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Pradaxa.
The CHMP considered that the benefits of the medicine outweigh its risk and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Preotact er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Preotact’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Prepandrix opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Prepandrix.
The CHMP decided that Prepandrix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Prevenar 13 opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Prevenar 13.
The CHMP decided that Prevenar 13’s benefits are greater than its risks and recommended that it be granted marketing authorisation.
CHMP besluttede, at fordelene ved Prezista opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Prezista.
The CHMP decided that Prezista’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Pritor opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Pritor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Prolia opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Prolia.
The CHMP decided that Prolia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Protaphane opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Protaphane.
The CHMP decided that Protaphane’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Protelos opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Protelos’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Rapamune opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Rapamune.
The CHMP decided that Rapamune’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Rapilysin opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Rapilysin.
The CHMP decided that Rapilysin’s benefits are greater than its risks for and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Rapiscan opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Rapiscan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Rasilamlo opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Rasilamlo.
The CHMP decided that Rasilamlo’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Rasilez HCT opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Rasilez HCT.
The CHMP decided that Rasilez HCT’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Rebetol opvejer risiciene og anbefalede udstedelse af en markedsføringstilladelse for Rebetol.
The CHMP decided that Rebetol’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Rebif opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Rebif’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Regranex er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Regranex.
The CHMP decided that Regranex’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Relistor opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Relistor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Remicade opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Remicade’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Renagel opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Renagel.
The CHMP decided that Renagel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Replagal opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Replagal’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Resolor opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Resolor.
The CHMP decided that Resolor’s benefits are greater than its risks and recommended that it be given marketing authorisation..
CHMP besluttede, at fordelene ved Revlimid opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Revlimid’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Revolade opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Revolade.
The CHMP decided that Revolade’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Rienso opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Rienso.
The CHMP decided that Rienso’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Rilutek opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Rilutek.
The CHMP decided that Rilutek’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ristaben opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Ristaben’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ristfor opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Ristfor.
The CHMP decided that Ristfor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Rotarix opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Rotarix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved RotaTeq opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for RotaTeq.
The CHMP decided that RotaTeq’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ryzodeg opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Ryzodeg.
The CHMP decided that Ryzodeg’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Sifrol opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Sifrol.
The CHMP decided that Sifrol’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Siklos er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Siklos’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Silgard opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Silgard.
The CHMP decided that Silgard’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Silodyx opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Silodyx.
The CHMP decided that Silodyx’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Simponi opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Simponi’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Soliris opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Soliris.
The CHMP decided that the benefits of Soliris are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Somavert opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Somavert.
The CHMP decided that the benefits of Somavert are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved SonoVue opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for SonoVue.
The CHMP decided that SonoVue’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Sprimeo HCT opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Sprimeo HCT.
The CHMP decided that Sprimeo HCT’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Sprycel opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Sprycel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Stocrin opvejer risiciene ved antiviral kombinationsbehandling af hiv-smittede voksne, unge og børn i alderen tre år og derover.
The CHMP decided that Stocrin’s benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents, and children three years of age and older.
CHMP besluttede, at fordelene ved Sustiva opvejer risiciene ved antiviral kombinationsbehandling af hiv-smittede voksne, unge og børn i alderen tre måneder og derover.
The CHMP decided that Sustiva’s benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents and children three months of age and older.
CHMP besluttede, at fordelene ved Sutent opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Sutent’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Sycrest opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Sycrest til behandling af moderate til svære maniske episoder hos patienter med bipolar lidelse.
The CHMP decided that Sycrest’s benefits are greater than its risks and recommended that it be given marketing authorisation for the treatment of moderate to severe manic episodes in patients with bipolar disorder.
CHMP besluttede, at fordelene ved Synagis opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Synagis.
The CHMP decided that Synagis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved TachoSil opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for TachoSil.
The CHMP decided that TachoSil’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Tamiflu opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Tamiflu.
The CHMP decided that Tamiflu’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Tarceva er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Tarceva.
The CHMP decided that Tarceva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Tasigna opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Tasigna’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Taxotere opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Taxotere’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Temodal er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Temodal.
The CHMP decided that Temodal’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Tesavel opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Tesavel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Thymanax opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Thymanax.
Therefore, the CHMP decided that Thymanax’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Toujeo opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Toujeo
The CHMP decided that Toujeo’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Toviaz opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Toviaz’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Tracleer opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Tracleer.
The CHMP decided that Tracleer’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Travatan opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Travatan.
The CHMP decided that Travatan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Tresiba opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Tresiba.
The CHMP decided that Tresiba’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Trisenox opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Trisenox’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Tygacil er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Tygacil.
The CHMP decided that Tygacil’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Tyverb opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Tyverb.
The CHMP decided that Tyverb’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Urorec opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Urorec.
The CHMP decided that Urorec’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved vaccinen opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Pumarix.
The CHMP decided that the vaccine’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved vaccinen opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that the vaccine’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Valdoxan opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Valdoxan.
Therefore, the CHMP decided that Valdoxan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Vaniqa er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Vaniqa.
The CHMP decided that Vaniqa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Vantavo er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse..
The CHMP decided that Vantavo’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Vectibix opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Vectibix.
The CHMP concluded that Vectibix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Velcade opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Velcade.
The CHMP decided that Velcade’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Velmetia opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Velmetia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ventavis opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Ventavis.
The CHMP decided that Ventavis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Vfend opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Vfend.
The CHMP decided that Vfend’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Viagra opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Viagra.
The CHMP decided that Viagra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Vidaza opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Vidaza.
The CHMP decided that Vidaza’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Vimpat opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Vimpat’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Viracept opvejer risiciene ved antiretroviral kombinationsbehandling af voksne, unge og børn i alderen tre år eller derover, der er smittet med HIV-1.
The CHMP decided that Viracept’s benefits are greater than its risks in antiviral combination treatment of HIV-1 infected adults, adolescents and children of three years of age and older.
CHMP besluttede, at fordelene ved ViraferonPeg er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for ViraferonPeg.
The CHMP decided that ViraferonPeg’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Viread opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Viread’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Visudyne opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Visudyne’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Volibris opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Volibris’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Xarelto opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Xarelto.
The CHMP decided that Xarelto’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Xelevia opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Xelevia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Xeloda opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Xeloda.
The CHMP decided that Xeloda’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Xiapex opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Xiapex.
The CHMP decided that Xiapex’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Xolair opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Xolair.
The CHMP decided that Xolair’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Xyrem opvejer risiciene.
The CHMP decided that Xyrem’s benefits are greater than its risks.
CHMP besluttede, at fordelene ved Yttriga er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Yttriga.
The CHMP decided that Yttriga’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Zavesca opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Zavesca’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Zebinix opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Zebinix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Zeffix opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Zeffix.
The CHMP decided that Zeffix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Zerit opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Zerit’s benefits are greater than its risks and recommended that it be given marketing authorisation.